Healthcare / Drug Manufacturers - GeneralHKSE
$3.54
+0.02 (+0.57%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 32% · confianza 23%
FCF escenarios
weak_data · normalized FCF $450.8M · quality 56.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
44/100
C
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$4.5B
P/E
9.8x
↓EV/EBITDA
1.5x
↓ROE
5.4%
↑Gross Margin
38.0%
↓Debt/Equity
0.27
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+2.7%
FCF CAGR
+37.2%
FCF margin
22.3%
FCF / Net income
3.65x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $6.48B · net income $396.3M · FCF $1.45B
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $6.48B | $6.48B | $7.26B | $6.77B | $5.99B |
| Net Income | $396.3M | $396.3M | $521.8M | $590.2M | $582.9M |
| EBITDA | $1.22B | $1.22B | $1.42B | $1.49B | $1.53B |
| EPS | 0.31 | 0.31 | 0.41 | 0.46 | 0.46 |
| Gross Margin | 38.0% | 38.0% | 39.6% | 42.0% | 43.3% |
| Operating Margin | 12.4% | 12.4% | 13.6% | 16.7% | 20.0% |
| Net Margin | 6.1% | 6.1% | 7.2% | 8.7% | 9.7% |
| Balance Sheet | |||||
| Debt/Equity | 0.27 | 0.27 | 0.34 | 0.24 | 0.25 |
| Current Ratio | 5.72 | 5.72 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $1.45B | $1.45B | $-158.6M | $450.8M | $559.7M |
| Returns | |||||
| ROE | 5.4% | 5.4% | 7.2% | 8.6% | 9.0% |
| Valuation | |||||
| P/E | 9.83 | 9.83 | 12.37 | 13.89 | 12.22 |
| EV/EBITDA | 1.51 | 1.51 | 3.38 | 4.75 | 3.32 |
| P/B | 0.62 | 0.62 | 0.90 | 1.19 | 1.11 |
| Growth & Yield | |||||
| Revenue Growth | -10.7% | -10.7% | 7.2% | 13.0% | — |
| EPS Growth | -24.4% | -24.4% | -10.9% | 0.0% | — |
| Dividend Yield | 5.8% | 5.8% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
0.4%
EPS terminal req.
$0.31
Spread vs growth
-24.8%
5Y implied EPS CAGR
4.2%
EPS terminal req.
$0.38
Spread vs growth
-28.6%
10Y implied EPS CAGR
7.0%
EPS terminal req.
$0.61
Spread vs growth
-31.4%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-24.6%
Start / end P/E
12.4x → 11.4x
EPS bridge
0.41 → 0.31
Residual
+1.9%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.